Fresenius Kabi Taiwan Limited Pharmaceutical Import Profile — Taiwan (DGFT 2022–2026)

Name: Fresenius Kabi Taiwan Limited Pharmaceutical Import Records from India — 3 Products, $1.8M FOB USD (DGFT 2022–2026)
Creator: TransData Nexus

Suresh Sormare

Explore

Fresenius Kabi Taiwan Limited — Pharmaceutical Importer Profile (2026) | 3 Products, $1.8M Trade | TransData Nexus

Fresenius Kabi Taiwan Limited

Pharmaceutical Importer · Taiwan · Oncology Focus · $1.8M Total Trade · DGFT Verified

Fresenius Kabi Taiwan Limited is a pharmaceutical importer based in Taiwan with a total trade value of $1.8M across 3 products in 1 therapeutic categories. Based on 38 verified import shipments from Indian Customs (DGFT) records, the company actively imports across multiple product segments. Fresenius Kabi Taiwan Limited sources from 1 verified Indian supplier, with Fresenius Kabi Oncology Limited accounting for 100.0% of imports.

Fresenius Kabi Taiwan Limited — Import Portfolio & Supplier Network

Fresenius Kabi Taiwan Limited import network — 3 products from Indian suppliers. Source: Indian Customs (DGFT).

Who Are the Verified Indian Suppliers to Fresenius Kabi Taiwan Limited?

Customs-verified supplier relationships from Indian DGFT records

Supplier	Value	Shipments	Share
Fresenius Kabi Oncology Limited	$245.9K	11	100.0%

Fresenius Kabi Taiwan Limited sources from 1 verified Indian supplier across 11 distinct formulations. The sourcing is highly concentrated — Fresenius Kabi Oncology Limited accounts for 100.0% of total imports, indicating a strategic single-source relationship.

Formulation	Value	Ships
Kemoplatcisplatinbp INJ.50MG/50ML vialbno.87230311aa87230311ab & 87230357ac manufacturing .dt.07/23 & 08/23 exp.dt.06/25	$50.0K	1
Kemoplat cisplatin BP INJ. 50MG/50mlvial batch no. 87230357ab manufacturing . dt. 08/2023 exp. dt.	$50.0K	1
Fytosid etoposide USP injection	$36.3K	1
Kemoplat ( cisplatin ) BP INJ. 50MG/50mlvialbatch no. 87240190ad mfg. dt. 05/2024 exp. dt.	$35.8K	1
Fytosid etoposide USP INJ. 100MG/5ML vial batch no. 87230417aa manufacturing . dt. 09/2023 exp. dt.	$18.1K	1
Kemocarb (carboplatin) INJ. BP 450MG/45ML vial batch no. 87240170ac mfg. dt. 05/2024 exp. dt.	$17.8K	1
Intaxel paclitaxel USP INJ.30MG/5mlbatch no.87230431aa manufacturing .dt.09/2023 &	$13.3K	1
Fytosid etoposide USP INJ.100MG/5mlbatch no.87230271af87230346ad manufacturing .dt.06/202307/2023 &	$11.6K	1
Gemita gemcitabine USP INJ. 200MG/vial batch no. 87230444ab manufacturing . dt. 10/2023 exp. dt.	$6.7K	1
Irinotel (irinotecan) hcl INJ. 100MG/5mlvialbatch no. 87240162bb mfg. dt. 05/2024 exp. dt.	$4.7K	1
Gemita ( gemcitabine ) USP INJ. 200MG/vial batch no. 87240029af mfg. dt. 01/2024 exp. dt.	$1.6K	1

Import Portfolio — Top 3 by Import Value

#	Product	Category	Value	Ships	Share	Rk
1	Cisplatin	Oncology	$1.0M	20	3.1%	2
2	Carboplatin	Oncology	$697.2K	14	1.0%	16
3	Etoposide	Oncology	$135.5K	4	1.3%	13

Fresenius Kabi Taiwan Limited imports 3 pharmaceutical products across 1 categories into Taiwan totaling $1.8M.

Fresenius Kabi Taiwan Limited — Corporate Profile & Information

Company type, headquarters, distribution network, and industry role

1Company Overview

Fresenius Kabi Taiwan Limited is a subsidiary of the global healthcare company Fresenius Kabi, specializing in lifesaving medicines and technologies for infusion, transfusion, and clinical nutrition. Established in 2002, the company is headquartered in Taipei City, Taiwan, at 5F., No. 30,32, Sec. 3, Ren-ai Rd., Da-an Dist., Taipei City 106463, Taiwan (R.O.C.). (taiwan.ahk.de) Fresenius Kabi Taiwan Limited plays a pivotal role in Taiwan's pharmaceutical distribution network, focusing on the importation and distribution of finished pharmaceutical formulations, particularly in the oncology therapeutic category.

2Distribution Network

While specific details about Fresenius Kabi Taiwan Limited's warehouse locations and logistics capabilities are not publicly disclosed, the company's strategic position in Taipei City suggests a centralized distribution model. This centralization likely facilitates efficient logistics and broad geographic coverage within Taiwan. Given Fresenius Kabi's global presence, it is reasonable to infer that the Taiwanese subsidiary benefits from the parent company's established logistics infrastructure, potentially extending its reach beyond Taiwan to other regions in the Asia-Pacific area.

3Industry Role

Fresenius Kabi Taiwan Limited operates primarily as a pharmaceutical importer and distributor, focusing on the oncology sector. By importing finished pharmaceutical formulations from India, the company serves as a critical link in Taiwan's pharmaceutical supply chain, ensuring the availability of essential cancer medications. Its role is integral to the healthcare system, providing hospitals and clinics with necessary treatments for critically and chronically ill patients.

TransData Nexus Research · Company registries, industry databasesMar 2026

Supplier Relationship Intelligence — Fresenius Kabi Taiwan Limited

Sourcing concentration, supply chain resilience, and strategic implications

1Sourcing Concentration Analysis

Fresenius Kabi Taiwan Limited's sourcing strategy exhibits a high degree of concentration, importing exclusively from a single supplier: Fresenius Kabi Oncology Limited. This supplier relationship accounts for all 38 shipments and 100% of the imported products, indicating a strategic choice to maintain consistency and quality control. However, this single-source dependency also introduces potential risks, such as supply chain disruptions or price fluctuations. The absence of alternative suppliers suggests a need for strategic diversification to mitigate these risks.

2Supply Chain Resilience

The resilience of Fresenius Kabi Taiwan Limited's supply chain is closely tied to its exclusive relationship with Fresenius Kabi Oncology Limited. While this partnership ensures product consistency, it also means that any disruptions at the supplier's end could significantly impact the Taiwanese market. The lack of backup suppliers and limited formulation diversity further heighten this vulnerability. Additionally, the reliance on a single shipping route exposes the supply chain to potential logistical challenges. Ensuring regulatory compliance of the key supplier is crucial to maintain uninterrupted supply and uphold product quality standards.

Strategic Implications

Importing Pharmaceuticals into Taiwan — Regulatory Framework

Regulatory authority, GMP requirements, import licensing for Taiwan

1Regulatory Authority & Framework

In Taiwan, the Food and Drug Administration (FDA) under the Department of Health is the primary regulatory body overseeing pharmaceutical imports. The key legislation governing pharma imports includes the Pharmaceutical Affairs Act and the Pharmaceutical Good Manufacturing Practice (GMP) Regulations. The marketing authorization pathway for Indian generics involves obtaining approval from the Taiwanese FDA, which assesses the safety, efficacy, and quality of the products before granting import licenses. This process ensures that imported generics meet Taiwan's stringent standards for pharmaceutical products. (fda.gov.tw)

2Import Licensing & GMP

Import licensing requirements in Taiwan stipulate that applicants must possess the eligibility of a pharmaceutical firm. Priority is given to manufacturers that comply with the Pharmaceutical GMP Regulations. For Indian exporters, this means obtaining GMP certification recognized by the Taiwanese FDA, such as EU GMP, WHO GMP, or PIC/S. Additionally, wholesale distribution authorization is required to import and distribute pharmaceutical products within Taiwan. These certifications and authorizations are essential for ensuring product quality and regulatory compliance in the Taiwanese market. (fda.gov.tw)

Quality & Labeling

Fresenius Kabi Taiwan Limited — Procurement Pattern Analysis

Product strategy, sourcing profile, and market positioning

1Product Strategy

Fresenius Kabi Taiwan Limited's focus on oncology products aligns with the growing demand for cancer treatments in Taiwan. The importation of finished pharmaceutical formulations, such as Cisplatin, Carboplatin, and Etoposide, addresses critical therapeutic needs in the oncology sector. This strategic focus is driven by the high incidence of cancer and the necessity for effective treatment options, positioning the company as a key player in enhancing patient care for critically ill individuals.

2Sourcing Profile

Fresenius Kabi Taiwan Limited's sourcing strategy is centered on importing generic drugs from India, particularly in the oncology category. The preference for finished pharmaceutical formulations over raw APIs or bulk drugs indicates a focus on ready-to-use products that meet the immediate needs of healthcare providers. India's established pharmaceutical manufacturing capabilities and cost-effectiveness make it a strategic partner for sourcing these products, ensuring a reliable supply of essential medications to the Taiwanese market.

3Market Positioning

By importing and distributing oncology medications, Fresenius Kabi Taiwan Limited serves the hospital and healthcare sectors in Taiwan. The company's product mix positions it to meet the needs of critically and chronically ill patients, particularly those requiring cancer treatments. This focus on hospital supply underscores the company's commitment to enhancing patient care and supporting healthcare institutions in delivering effective treatments.

Seller's Guide — How to Become a Supplier to Fresenius Kabi Taiwan Limited

Opportunity assessment, qualifications, and practical approach strategy

1Opportunity Assessment

There is a realistic opportunity for new Indian suppliers to enter the Taiwanese market by offering alternative oncology products or formulations that meet the regulatory standards and therapeutic needs of Taiwan. Diversifying the supplier base can enhance supply chain resilience and provide Fresenius Kabi Taiwan Limited with options to mitigate risks associated with single-source dependency. Identifying gaps in the current sourcing strategy, such as unmet therapeutic needs or product shortages, can present avenues for new suppliers to establish partnerships and expand their market presence.

2Requirements & Qualifications

Indian exporters aiming to supply Fresenius Kabi Taiwan Limited and the broader Taiwanese market must obtain GMP certifications recognized by the Taiwanese FDA, such as EU GMP, WHO GMP, or PIC/S. Additionally, wholesale distribution authorization is required to import and distribute pharmaceutical products within Taiwan. Compliance with these certifications and authorizations is essential for ensuring product quality, regulatory compliance, and successful market entry. (fda.gov.tw)

3How to Approach

Frequently Asked Questions — Fresenius Kabi Taiwan Limited

What products does Fresenius Kabi Taiwan Limited import from India?

Fresenius Kabi Taiwan Limited imports 3 pharmaceutical products across 1 categories. Top imports: Cisplatin ($1.0M), Carboplatin ($697.2K), Etoposide ($135.5K).

Who supplies pharmaceuticals to Fresenius Kabi Taiwan Limited from India?

Fresenius Kabi Taiwan Limited sources from 1 verified Indian suppliers. The primary supplier is Fresenius Kabi Oncology Limited (100.0% of imports, $245.9K).

What is Fresenius Kabi Taiwan Limited's total pharmaceutical import value?

Fresenius Kabi Taiwan Limited's total pharmaceutical import value from India is $1.8M, based on 38 verified shipments in Indian Customs (DGFT) data.

What therapeutic categories does Fresenius Kabi Taiwan Limited focus on?

Fresenius Kabi Taiwan Limited imports across 1 categories. The largest: Oncology (100.0%).

Get Full Fresenius Kabi Taiwan Limited Import Intelligence

Access shipment-level details, supplier connections, pricing data, and competitive analysis. TransData Nexus provides verified Indian Customs (DGFT) data trusted by pharmaceutical trade professionals worldwide.

Contact for Data Access Request Live Demo

Official References & Regulatory Resources

Verify import regulations and drug registration requirements with the agencies above.

Research Methodology & Data Transparency

Suresh Sormare

Verified Author

Pharmaceutical Export-Import Analyst & Trade Intelligence Expert

Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.

linkedin.com/in/sureshsormare

Primary Data Source

All trade data is sourced from Indian Customs (DGFT) official shipping bill records — the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.

Data Source & Methodology

Trade data sourced from Indian Customs (DGFT) export shipment records. Values represent FOB export value in USD. Profile aggregates 4 company name variants from customs records. For current shipment-level data, contact TransData Nexus.